Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX

Oncotarget
Theodore VougiouklakisYo Matsuo

Abstract

Protein methyltransferase SUV39H2 was reported to methylate histone H2AX at lysine 134 and enhance the formation of phosphorylated H2AX (γ-H2AX), which causes chemoresistance of cancer cells. We found that a series of imidazo[1,2-a]pyridine compounds that we synthesized could inhibit SUV39H2 methyltransferase activity. One of the potent compounds, OTS193320, was further analyzed in in vitro studies. The compound decreased global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggered apoptotic cell death. Combination of OTS193320 with doxorubicin (DOX) resulted in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX. Further optimization of inhibitors and their in vivo analysis identified a compound, OTS186935, which revealed significant inhibition of tumor growth in mouse xenograft models using MDA-MB-231 breast cancer cells and A549 lung cancer cells without any detectable toxicity. Our results suggest that the SUV39H2 inhibitors sensitize cancer cells to DOX by reduction of γ-H2AX levels in cancer cells, and collectively demonstrate that SUV39H2 inhibition warrants further investigation as a novel anti-cancer therapy.

References

Apr 6, 2002·Science·Arkady CelesteAndré Nussenzweig
Jun 7, 2003·Nature Cell Biology·Arkady CelesteAndré Nussenzweig
Jul 6, 2004·Nature Cell Biology·Ryuji HamamotoYusuke Nakamura
Jan 31, 2006·Cancer Science·Ryuji HamamotoYoichi Furukawa
Apr 13, 2006·JAMA : the Journal of the American Medical Association·Donald A BerryEric P Winer
Apr 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Manfred KaufmannGunter von Minckwitz
Dec 18, 2007·Molecular Cell·J Wade Harper, Stephen J Elledge
Feb 8, 2008·Nature Reviews. Cancer·Thomas HelledayRicky A Sharma
Mar 14, 2008·The New England Journal of Medicine·Manel Esteller
Dec 28, 2010·Gynecologic Oncology·Andreas H BrunnerHermann Brustmann
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Aug 16, 2011·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Anika NagelkerkePaul N Span
Aug 19, 2011·Neoplasia : an International Journal for Oncology Research·Hyun-Soo ChoRyuji Hamamoto
Jun 27, 2013·Blood·Scott R DaigleRoy M Pollock
Feb 4, 2014·Cancer Science·Noriko Hosoya, Kiyoshi Miyagawa
Jun 21, 2014·Future Oncology·Mark R KelleyMelissa L Fishel
Dec 10, 2014·Nature Communications·Kenbun SoneRyuji Hamamoto
Feb 25, 2015·Current Oncology Reports·Daniel G Stover, Nikhil Wagle
Sep 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E SenkusUNKNOWN ESMO Guidelines Committee
Oct 27, 2015·Translational Oncology·Martin MutongaHouda Alachkar
Nov 21, 2015·Oncotarget·Theodore VougiouklakisRyuji Hamamoto
Feb 3, 2018·Cancer Management and Research·Claudia OmariniFederico Piacentini

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
xenografts
PCR
transfection
confocal microscopy

Software Mentioned

Image J
Aperio Nuclear
ScanScope XT
Kaplan Plotter

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.